B. Metzler seel. Sohn & Co. Holding AG Invests $572,000 in Elanco Animal Health Incorporated (NYSE:ELAN)

B. Metzler seel. Sohn & Co. Holding AG acquired a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 38,922 shares of the company's stock, valued at approximately $572,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Benjamin F. Edwards & Company Inc. grew its stake in Elanco Animal Health by 337.7% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company's stock valued at $26,000 after purchasing an additional 1,361 shares in the last quarter. ORG Wealth Partners LLC acquired a new position in Elanco Animal Health during the third quarter worth $29,000. ORG Partners LLC acquired a new position in Elanco Animal Health during the second quarter worth $31,000. nVerses Capital LLC bought a new stake in Elanco Animal Health during the second quarter worth $32,000. Finally, AM Squared Ltd acquired a new stake in Elanco Animal Health in the third quarter valued at $34,000. Institutional investors and hedge funds own 97.48% of the company's stock.

Wall Street Analyst Weigh In

ELAN has been the topic of a number of research analyst reports. Barclays upped their target price on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an "overweight" rating in a report on Friday, November 8th. Morgan Stanley cut Elanco Animal Health from an "overweight" rating to an "equal weight" rating and cut their price objective for the company from $17.00 to $15.00 in a research report on Thursday, September 19th. Finally, Stifel Nicolaus reissued a "buy" rating and set a $20.00 target price on shares of Elanco Animal Health in a report on Thursday, September 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Elanco Animal Health presently has an average rating of "Hold" and an average price target of $17.14.

Elanco Animal Health Stock Performance

ELAN traded up $0.03 during trading on Monday, hitting $13.39. The stock had a trading volume of 4,405,326 shares, compared to its average volume of 4,749,236. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The company has a 50 day moving average price of $13.68 and a 200-day moving average price of $14.72. Elanco Animal Health Incorporated has a one year low of $11.40 and a one year high of $18.80. The firm has a market cap of $6.62 billion, a price-to-earnings ratio of 33.48, a P/E/G ratio of 1.39 and a beta of 1.41.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, beating analysts' consensus estimates of $0.12 by $0.01. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the previous year, the business earned $0.18 earnings per share. The firm's quarterly revenue was down 3.6% on a year-over-year basis. As a group, research analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.